Ad hoc announcement pursuant to Art. 53 LR - Ypsomed

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site

03/27/2024 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf - Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses. The transfer to MTD will ensure the long-term supply of a unique pen needle offering. With this step, Ypsomed is focusing its diabetes care business even more strongly on the further development and marketing of the innovative mylife Loop insulin pump solution. As part of its growth strategy, Ypsomed will invest over CHF 100 million over the next four years in the expansion of capacities for autoinjectors at the Solothurn site.

Ypsomed doubles profits and confirms outlook

11/15/2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million).

Samuel Künzli succeeds Niklaus Ramseier as CFO and member of the Executive Board

09/29/2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be available to the company for strategic projects. His successor is Samuel Künzli, who will start his position as CFO on 01 April 2024.

Ypsomed concludes a long-term supply agreement for large quantities of autoinjectors

09/20/2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications. Ypsomed is in the process of substantially increasing its annual manufacturing capacity in several steps until 2031.

Ypsomed doubles profits and confirms outlook

05/24/2023 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 497.5 million in the 2022/23 financial year (previous year: CHF 464.8 million). Adjusted for the effect of the divestment of DiaExpert, continuing business demonstrated growth of 16%, or approximately 19% currency adjusted. The reported growth in turnover corresponds to a growth of 7% compared to the previous year. At constant exchange rates compared to the previous year, this would have represented an increase of around 10%. With this growth, the company has significantly increased both its operating profit (EBIT) from CHF 28.6 million to CHF 60.6 million as well as more than doubled its net profits to CHF 51.3 million (previous year CHF 23.1 million). Ypsomed confirms the outlook for the 2023/24 financial year.